Main Menu

A Radical Treatment for Insulin Pricing

Leemore S. Dafny
New England Journal of Medicine
April 6, 2022

In 2021, the Food and Drug Administration approved the first interchangeable biosimilar insulin product that could be substituted for insulin glargine (long-acting insulin). Interchangeable biosimilars have the potential to substantially reduce spending on biological products, similar to generic versions of small-molecule brand name medications. However, when deductibles were reset at the beginning of 2022, the list price of the insulin biosimilar was only 5% less than the brand name insulin. In the Perspective article “A Radical Treatment for Insulin Pricing,” Partner Leemore Dafny opines that a regulatory or disruptive business fix is needed to address such costs and suggests that such a fix could better derive from the private than from the public sector.

Read the article here (subscription required).


Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.